Possible biased analgesic of hydromorphone through the G protein-over β-arrestin-mediated pathway: cAMP, CellKey™, and receptor internalization analyses.

Analgesics, Opioid / adverse effects Cyclic AMP GTP-Binding Proteins / metabolism HEK293 Cells Humans Hydromorphone / adverse effects Receptors, Opioid, mu / metabolism Signal Transduction / drug effects beta-Arrestins / metabolism
Biased agonist G protein Hydromorphone β-arrestin μ-opioid receptor

Journal

Journal of pharmacological sciences
ISSN: 1347-8648
Titre abrégé: J Pharmacol Sci
Pays: Japan
ID NLM: 101167001

Informations de publication

Date de publication:
Jun 2019
Historique:
received: 03 04 2019
revised: 06 06 2019
accepted: 10 06 2019
pubmed: 20 7 2019
medline: 10 1 2020
entrez: 20 7 2019
Statut: ppublish

Résumé

Morphine, fentanyl, and oxycodone are widely used as analgesics, and recently hydromorphone has been approved in Japan. Although all of these are selective for μ-opioid receptors (MORs) and have similar structures, their analgesic potencies and adverse effects (AEs) are diverse. Recent molecular analyses of MOR signaling revealed that the G protein-mediated signaling pathway causes analgesic effects and the β-arrestin-mediated signaling pathway is responsible for AEs. We used several cell-based analyses that selectively measure cellular responses activated by either G protein- or β-arrestin-mediated pathways. GloSensor™ cAMP, CellKey™, and receptor internalization assays were performed with four different types of cells stably expressing differentially labelled MOR. EC

Identifiants

DOI: 10.1016/j.jphs.2019.06.005 PMID: 31320243
pubmed: 31320243
pii: S1347-8613(19)34170-2
doi: 10.1016/j.jphs.2019.06.005
pii:
doi:

Substances chimiques

Analgesics, Opioid 0
Receptors, Opioid, mu 0
beta-Arrestins 0
Cyclic AMP E0399OZS9N
GTP-Binding Proteins EC 3.6.1.-
Hydromorphone Q812464R06

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

171-177

Informations de copyright

Copyright © 2019 The Authors. Production and hosting by Elsevier B.V. All rights reserved.

Auteurs

Sei Manabe (S)

Department of Anesthesiology and Resuscitology, Okayama University, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, 2-5-1, Shikatacho, Okayama 700-8558, Japan; Division of Cancer Pathophysiology, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan; Department of Anesthesiology and Critical Care Medicine, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.

Kanako Miyano (K)

Division of Cancer Pathophysiology, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.

Yuriko Fujii (Y)

Division of Cancer Pathophysiology, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan; Department of Anesthesiology and Pain Medicine, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan.

Kaori Ohshima (K)

Division of Cancer Pathophysiology, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan; Laboratory of Pharmacology and Therapy, Graduate School of Pharmaceutical Sciences, Tokyo University of Science, 2641 Yamazaki, Noda, Chiba 278-0022, Japan.

Yuki Yoshida (Y)

Division of Cancer Pathophysiology, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan; Laboratory of Molecular Pathology and Metabolic Disease, Graduate School of Pharmaceutical Sciences, Tokyo University of Science, 2641 Yamazaki, Noda, Chiba 278-0022, Japan.

Miki Nonaka (M)

Division of Cancer Pathophysiology, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.

Miaki Uzu (M)

Division of Cancer Pathophysiology, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.

Yoshikazu Matsuoka (Y)

Department of Intensive Care Unit, Okayama University Hospital, 2-5-1, Shikatacho, Okayama 700-8558, Japan.

Tetsufumi Sato (T)

Department of Anesthesiology and Critical Care Medicine, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.

Yasuhito Uezono (Y)

Division of Cancer Pathophysiology, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan; Division of Supportive Care Research, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan; Innovation Center for Supportive, Palliative and Psychosocial Care, National Cancer Center, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan. Electronic address: yuezono@ncc.go.jp.

Hiroshi Morimatsu (H)

Department of Anesthesiology and Resuscitology, Okayama University, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, 2-5-1, Shikatacho, Okayama 700-8558, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Agents du système nerveux central › Dépresseurs du système nerveux central › Stupéfiants › Analgésiques morphiniques › Possible biased analgesic of hydromorphone...
questionsmedicales.fr › Acides nucléiques, nucléotides et nucléosides › Nucléotides › Ribonucléotides › Nucléotides adényliques › AMP cyclique › Possible biased analgesic of hydromorphone...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines et peptides de signalisation intracellulaire › Protéines G › Possible biased analgesic of hydromorphone...
questionsmedicales.fr › Cellules › Cellules épithéliales › Cellules HEK293 › Possible biased analgesic of hydromorphone...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Possible biased analgesic of hydromorphone...
questionsmedicales.fr › Composés polycycliques › Hydrocarbures aromatiques polycycliques › Phénanthrènes › Morphinanes › Dérivés de la morphine › Hydromorphone › Possible biased analgesic of hydromorphone...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Récepteurs de surface cellulaire › Récepteurs peptidiques › Récepteur aux neuropeptides › Récepteurs aux opioïdes › Récepteur mu › Possible biased analgesic of hydromorphone...
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Transduction du signal › Possible biased analgesic of hydromorphone...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Arrestines › bêta-Arrestines › Possible biased analgesic of hydromorphone...